brand logo

JENNIFER G. CHANG, MD, MEGHAN N. LEWIS, MD, AND MAGGIE C. WERTZ, MD

This is an updated version of the article that appeared in print.

Note: In May 2023, while this article was in production, the U.S. Food and Drug Administration approved fezolinetant (Veozah), a neurokinin 3 receptor antagonist, for treatment of moderate to severe vasomotor symptoms due to menopause. This article has been revised to incorporate information about this nonhormonal medication. 

Am Fam Physician. 2023;108(1):28-39

 This clinical content conforms to AAFP criteria for CME.

Author disclosure: No relevant financial relationships.

Menopausal symptoms are widespread and significantly impact quality of life. Common symptoms of menopause are vasomotor (i.e., hot flashes and night sweats) and genitourinary (e.g., vulvovaginal irritation and dryness, dyspareunia, urinary problems), although women may also experience changes in sexual function, mood, and sleep. Estrogen-containing hormone therapy is effective treatment for vasomotor symptoms. Nonhormonal medications for vasomotor symptoms include selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, gabapentin, and fezolinetant, which is a neurokinin 3 receptor antagonist [updated]. Selective serotonin reuptake inhibitors should not be administered to women taking tamoxifen. Cognitive behavior therapy and clinical hypnosis are effective for short-term reduction of vasomotor symptoms and associated sleep disturbances, but data are lacking to support the effectiveness of other nonpharmacologic treatments such as herbal or botanical supplements, exercise, and acupuncture. Hormone-free vaginal moisturizers are noninferior to estrogen-based therapies for treating genitourinary syndrome of menopause. Other treatment options for vaginal dryness and dyspareunia associated with menopause include ospemifene and intravaginal dehydroepiandrosterone. Management of menopausal symptoms should involve shared decision-making that is informed by the best available evidence and individual risks and preferences.

The menopausal transition (perimenopause) is characterized by a persistent decline in ovarian function and hormonal fluctuations that may cause bothersome vasomotor (i.e., hot flashes and night sweats) and genitourinary symptoms (e.g., vulvovaginal irritation and dryness, dyspareunia, urinary problems), and affect mood, sleep, sexual function, bone health, and overall quality of life.1 Perimenopause usually begins during the fifth decade of life and lasts several years before completion of natural menopause, a clinical diagnosis made only after cessation of menses for 12 consecutive months. Vasomotor symptoms may affect as many as 80% of women worldwide and last, on average, a total of seven to eight years, including four to five years after the final menstrual period.2–4 Vasomotor symptoms account for 1.5 million excess outpatient visits per year and an additional $330 million in annual U.S. health care costs when left untreated.5 Genitourinary syndrome of menopause affects up to 50% of women worldwide; unlike vasomotor symptoms, it is progressive without treatment.6 Figure 1 suggests an approach for applying the best available evidence and an individualized risk-benefit assessment to guide shared decision-making about natural menopause symptoms.7–11,54 [updated] This article does not discuss surgical menopause or premature menopause (also known as primary ovarian insufficiency). The use of the term women is intended to include cisgender women and other people with ovaries.

Already a member/subscriber?  Log In

Subscribe

From $165
  • Immediate, unlimited access to all AFP content
  • More than 130 CME credits/year
  • AAFP app access
  • Print delivery available
Subscribe

Issue Access

$59.95
  • Immediate, unlimited access to this issue's content
  • CME credits
  • AAFP app access
  • Print delivery available

Article Only

$25.95
  • Immediate, unlimited access to just this article
  • CME credits
  • AAFP app access
  • Print delivery available
Purchase Access:  Learn More

Continue Reading

More in AFP

More in PubMed

Copyright © 2023 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP.  See permissions for copyright questions and/or permission requests.

Copyright © 2024 American Academy of Family Physicians. All Rights Reserved.